Role of gut microbe-derived metabolites in cardiometabolic diseases: Systems based approach

Yang Cao¹,⁴, Ruben Aquino-Martinez ²,⁴, Evan Hutchison², Hooman Allayee³,⁵, Aldons J. Lusis¹,⁵, Aldons J. Lusis¹,⁵, Federico E. Rey²,⁵

ABSTRACT

Background: The gut microbiome influences host physiology and cardiometabolic diseases by interacting directly with intestinal cells or by producing molecules that enter the host circulation. Given the large number of microbial species present in the gut and the numerous factors that influence gut bacterial composition, it has been challenging to understand the underlying biological mechanisms that modulate risk of cardiometabolic disease.

Scope of the Review: Here we discuss a systems-based approach that involves simultaneously examining individuals in populations for gut microbiome composition, molecular traits using “omics” technologies, such as circulating metabolites quantified by mass spectrometry, and clinical traits. We summarize findings from landmark studies using this approach and discuss future applications.

Major Conclusions: Population-based integrative approaches have identified a large number of microbe-derived or microbe-modified metabolites that are associated with cardiometabolic traits. The knowledge gained from these studies provide new opportunities for understanding the mechanisms involved in gut microbiome–host interactions and may have potentially important implications for developing novel therapeutic approaches.

Keywords cardiometabolic diseases; systems genetics; gut microbiome; metabolomics

1. INTRODUCTION

The gut microbiome plays a critical role in host metabolism, influencing traits such as obesity, diabetes, and other disorders. Because the microbiome is highly complex, with hundreds of species, and because its composition is influenced by many factors (including the host’s diet, age, genetics, health, and lifestyle), it has been challenging to determine the mechanisms involved in microbiome–host interactions. Here, we discuss population-based approaches that are proving useful in understanding the molecular mechanisms mediating the effects of the microbiome on cardio-metabolic disorders. Particularly informative have been studies that integrate global “omics” data with physiological/clinical data in human or mouse cohorts to help understand mechanisms underlying complex traits such as cardiovascular disease. For example, gut microbiome composition obtained by sequencing can be integrated with metabolomics data in the host to identify which bacteria or metabolites mediate physiological microbe-host interactions. If host genetic data are incorporated into the analyses, the approach has been termed “systems genetics” (Box 1). Such data can be integrated using genetic mapping, correlation, or various types of modeling. Thus far, the most significant progress has come from integrating variation in microbiome composition, plasma metabolites, and clinical traits. The first section provides an overview of microbial metabolism in the gut. The second section discusses the environmental and genetic factors influencing gut microbes and bacterial-derived metabolites. The third section reviews our current understanding of microbe-derived metabolites involved in cardiometabolic diseases. The last section summarizes findings and discusses future prospects.

2. THE ROLE OF GUT MICROBES (DIRECT) AND RELATED METABOLITES (INDIRECT) IN NORMAL PHYSIOLOGY AND COMPLEX DISEASES

Mammals harbor diverse and dynamic microbial communities in their intestines that play key roles on host biology, including maturation of the immune system, breakdown of complex dietary components, vitamin production, energy harvesting, drug metabolism, and protection against
enteric pathogens. For example, germ-free (GF) mice are protected from developing diet-induced obesity and insulin resistance [3–5] have decreased levels of TNF-a in serum, and have increased lipid excretion relative to age and sex matched conventionally-raised animals [6]. A foundational study from Backhed and colleagues further demonstrated that gut microbes increase both nutrient absorption and hepatic lipogenesis, with colonized mice accumulating 60% more fat tissue than GF counterparts despite lower caloric intake [3].

Gut microbes can also affect host physiology through production of metabolites that act on specific receptors expressed in the intestine and in distant organs, impacting multiple cellular signaling cascades and causing epigenetic changes [7–12]. As discussed in further detail below, these metabolites are derived from various classes of dietary nutrients, including quaternary amines, amino acids, and carbohydrates (Table 1). Myriad effects related to gut and systemic physiology and cardiometabolic disease have been described for these molecules [13,14]. These paracrine and endocrine effects of gut microbial metabolites constitute a direct link between environmental exposures and host cellular function [15]. Furthermore, environmental exposures including Western-like diets, antibiotics, stress, and aging often lead to changes in microbial metabolism and production of metabolites or toxins that contribute to disease states [16,17].

Direct interactions between microbes or microbial components and the host also have major implications for host health. In this context, the intestinal epithelium constitutes a dynamic interface between the gut environment and the host. Acting as a physical and immune barrier, the gut epithelium plays an essential function to retain water and absorb nutrients, while avoiding microbial invasion [7,18]. Epithelial cells are covered by a mucus layer that contains digestive secretions, immune molecules, antimicrobial peptides, and cytokines, limiting the contact between gut microbes and luminal antigens with host epithelial cells [19]. Together, the epithelial cells and their tight junctions, which help seal off the epithelium, the mucus layer and the antimicrobial peptides contained within play a critical role in preventing trespassing microbes and their potentially harmful toxins from reaching underlying tissues. Thus, gut barrier integrity is critical in the prevention of intestinal and extraintestinal disorders. In this regard, human studies have consistently reported that changes in gut microbiome composition are associated with altered intestinal barrier function and increased circulating LPS levels [20,21]. While translocation of microbial components at low levels is key for priming innate defenses, chronic systemic inflammation induced by translocation of bacterial cellular components, including LPS and peptidoglycan fragments, is a potential mechanism by which gut bacteria contribute to cardiometabolic diseases [21].

3. FACTORS AFFECTING GUT BACTERIAL COMPOSITION

3.1. Environment

A large number of environmental factors, including delivery mode and diet, can influence the composition of the gut microbiome. Children that are delivered naturally, rather than by Caesarean section, tend to have more diverse gut microbiomes early in life [22]. Antibiotics cause large changes in the gut microbiome, although the degree of resulting perturbation is determined by many factors including age, duration of treatment, spectrum, and treatment route. Additionally, post-antibiotic environment including exposure to pathogenic and beneficial microbes impact microbiome composition after treatment [23]. Recently, pollutants and smoking have been shown to have an impact on gut microbiome composition [24]. The gut microbiome also changes as people age and microbiome signatures have been associated with healthy aging [25,26]. Furthermore, dietary interventions rich in nondigestible carbohydrates modulate the gut microbiome of old adults and have been associated with healthy aging [27]. Non-digestible carbohydrates are considered a major source of carbon and energy for intestinal microbes [28] and these can have a major impact the composition of the microbiome [29]. Dietary proteins are an important nitrogen source for bacteria [30], whereas fat, while generally considered to be less important to distal gut microbes, can still modulate microbiome composition [31,32].

3.2. Host genetics

Human and animal studies have provided evidence that host genetics also plays an important role in determining the composition and function of the gut microbiome. For example, family- and population-based analyses have yielded significant heritability estimates for a sizeable fraction of bacterial taxa [33]. Among a panel of 110 inbred mouse strains from the Hybrid Mouse Diversity Panel (HMDP), where confounding factors, such as dietary variation and age were controlled, heritability estimates for certain taxa were considerably higher than in humans [34]. Consistent with these observations, dozens of loci associated with gut bacterial abundance have been identified through genome-wide association studies (GWAS) in both mice and humans [34–36]. However, most loci have not been replicated across studies, at least in humans, even with sample sizes exceeding 1000 subjects [33,37–46]. The only two exceptions thus far have been the LCT and ABO loci, which are the basis for the lactase persistence trait and ABO blood group system, respectively. Across studies, the lactase non-persistence genotypes at LCT were associated with higher intestinal levels of bifidobacteria, which are able to break down lactose [47], and one study further provided evidence that the lead variant at LCT was causally associated with multiple dietary and metabolic phenotypes, including obesity and type 2 diabetes (T2D) [48]. By comparison, taxa associated with ABO were not the same across the three datasets in which this locus was identified [40,41,43]. A study using microbiome data from 1,046 healthy individuals showed that environmental factors
dominate over host genetics in determining gut microbiome composition [42]. As the field moves towards larger sample sizes and metagenomic sequencing (vs. 16S rRNA gene sequencing), association signals for gut bacteria abundance will be better refined. Furthermore, heritability estimates and genetic studies can be expanded to functional components of the gut microbiome, which may reveal another level of insight into how host genetics influences susceptibility to cardiometabolic diseases.

Another important aspect of host genetics is sex differences. It has proven difficult to demonstrate sex differences in gut microbial composition in humans, undoubtedly due to the impact of environmental and other factors, but sex differences are clearly observed in mice. For example, gut microbiota in the HMDP discussed above were studied for sex differences in composition [48]. A total of about 700 male and female mice from 89 matched strains were examined using 16S rRNA gene sequencing. When considering each strain independently, clear differences in microbiota composition and diversity were observed between sexes. Using PROCRUSTES analysis, the magnitude and direction of change for multiple bacterial species were different between strains, suggesting that the impact of sex depends on host genotype. However, when an entire mouse population was examined together using Bray–Curtis dissimilarity, no clear pattern differentiating males from females were observed. Thus, genetic variation between strains obscures sex differences when the entire population is examined together. Follow-up studies in a small number of strains showed that the sex differences were at least in part mediated by sex hormones and these sex differences were associated with differences in bile acid metabolites [48].

4. GUT MICROBE-DERIVED METABOLITES AND CARDIOMETABOLIC DISEASE

A number of gut bacteria-derived metabolites have been implicated in the development of cardiometabolic outcomes. In some cases, various dietary nutrients serve as the exogenous precursor that gut bacteria use to generate the metabolite in question. By contrast, metabolites first generated by the host can also be acted upon by gut bacteria, particularly those that are hydroxylated or otherwise modified for excretion through the kidney. A discussion of each of these classes of metabolites and their relationships to gut bacteria and cardiometabolic outcomes is provided below (Table 1 and Figure 2).

| Precursor or dietary nutrient | Metabolite | Target tissue | Biological Pathway(s) Affected |
|------------------------------|------------|---------------|-------------------------------|
| Choline, carnitine | TMAO | Liver | Adverse effects on lipid/glucose metabolism |
| Amino acids Tryptophan | IPA | Intestine | Improves barrier function |
| Phenylalanine Histidine | PAG | Platelets | Activates and promotes thrombosis |
| Tyrosine | Phenols | Kidney, intestine | Reduces kidney function, impairs insulin signaling |
| BCAAs | BCAAs | White adipose, skeletal muscle, liver, heart, kidney, and pancreas Intestine | Reduces epithelial barrier function, improves barrier function |
| Microbiota-accessible carbohydrates (MACs) Butyrate | Acetate | Liver, Regulatory T cells | Improves barrier function |
| Sterols Primary BAs | Propionate | Intestine | Increases blood pressure |
| | | | | |

*Table 1 — Characteristics of gut bacteria-derived metabolites associated with cardiometabolic traits.*

Figure 1: System genetics strategies. Molecular phenotypes across multiple biological scales — including the genome (G), transcripts (T), proteins (P), metabolites (M) and microbiome — are examined using “omics” technologies in populations exhibiting natural variation. Interactions (shown as arrows) can then be identified using genetic mapping, correlation structure, causal modeling, and network modeling. For example, based on natural variations of genes 1–4 (G1–4), interactions between the genes and related molecules can be modelled. These molecular interactions are then examined in the context of clinical variation in the population. Modified from Civelek and Lusis, Nat Rev Genet 2014.
5. METABOLITES DERIVED FROM QUATERNARY AMINES (CHOLINE/CARNITINE/TMAO)

Choline is an essential nutrient required for diverse biological functions ranging from synthesis of acetylcholine, a membrane component, to cell membrane signaling [49]. In humans, endogenous choline production is insufficient, and dietary sources are needed to prevent its deficiency [50]. In early life, the beneficial effects of choline are associated with the neurological health of the child during pregnancy [50], where maternal supplementation with dietary choline supports brain development, provides neural protection against metabolic and stress insults, and improves cognitive function [50].

More recently, choline was also recognized as a substrate for gut bacterial metabolism (Table 1). Wang and colleagues [17] carried out plasma metabolomics on a cohort of patients with and without coronary artery disease (CAD) and identified higher circulating levels of choline and the metabolite, trimethylamine N-oxide (TMAO), as being associated with atherosclerosis [17]. TMAO is the product of hepatic oxidation of the microbe-derived metabolite trimethylamine (TMA), which itself is generated from dietary choline by gut bacteria harboring glycyl radical enzyme choline TMA-lyase (CutC) [51]. TMA is rapidly absorbed from the intestine into the portal system and oxidized by flavin monoxygenases, primarily FM03, into TMAO [52]. Notably, TMAO can also be produced from dietary carnitine (Table 1), through either a minor route where TMA is directly generated from carnitine [53,54] or a major route involving two sequential bacterial reactions; the first generates gamma-butyrobetaine (γ-bb), which is then converted to TMAO by the enzymes encoded by γbb utilization (bbu) gene cluster. Several host-associated bacterial species from the order Clostridiales encode bbu-like gene clusters including *Emergencia timonensis* [54–56]. In either case, subsequent studies confirmed the proatherogenic effects of choline- or carnitine-derived TMAO on aortic lesion development in mouse models through pro-inflammatory and pro-coagulant effects [53,57]. In addition to atherosclerotic pathologies associated with TMAO, the FM03 enzyme has also been associated with metabolic disturbances, such as altered lipid and glucose metabolism [58–61]. Interestingly, insulin resistance increases FM03 activity in the liver of both human and mice, which leads to increased TMAO levels and metabolic dysfunction over time [58]. This may be related to the specific activation of endoplasmic reticulum stress kinase (PERK) by TMAO but not by choline or carnitine [62].

Gnotobiotic mouse studies suggest that exacerbated gut bacterial choline metabolism can influence choline bioavailability. Romano and colleagues identified members of the human gut microbiota that...
transform choline into TMA, leading to decreased choline availability to the host [63], which recapitulated aspects of diet-induced choline deficiency when the choline consuming bacteria represented a significant fraction of the microbiome [64]. Consistent with the role of choline in neural development, exacerbated maternal gut microbial metabolism of choline into TMA can alter brain development and influence behavior in the offspring potentially by decreasing sphingomyelin and acetylcysteine levels [64]. It is important to note that these studies were done using diets supplemented with free choline, which can be readily degraded under anaerobic conditions by gut microbes. However, the most abundant form of dietary choline is phosphatidylcholine, which is less available to TMA-producing species as the choline has to be hydrolyzed. Chittim et al. demonstrated that gut bacteria can hydrolyze phosphatidylcholine and release choline via phospholipase D enzyme and influence TMA production and potentially TMAO circulating levels [65]. Consistent with this, a recent study in healthy humans consuming four eggs daily showed no significant increase in TMAO levels whereas consumption of comparable levels of choline provided as a choline bitartrate supplement, which is readily available to bacteria, raised TMAO levels significantly and augmented platelet reactivity [66].

6. METABOLITES DERIVED FROM AMINO ACIDS

Protein digestion and amino acid absorption are relatively efficient processes in the small intestine, but approximately 3–12 g of undigested protein is available for colonic bacteria [67]. Protein fermentation in the gut has the potential to be detrimental for the host as it generates multiple potentially toxic metabolites, such as phenolic compounds [68,69]. For instance, bacterial production of phenyl derivatives by gut bacteria is associated with atherosclerosis and chronic kidney disease (CKD) [70,71].

6.1. Tryptophan

Tryptophan is an essential amino acid that cannot be produced by the human body and must be obtained through dietary proteins [72]. A small portion (about 1%) of ingested tryptophan is used for protein synthesis [73]. The majority of tryptophan is metabolized to a variety of biologically active compounds in different tissues, including serotonin, synthesis [73]. The majority of tryptophan is metabolized to a variety of small portion (about 1%) of ingested tryptophan is used for protein human body and must be obtained through dietary proteins [72]. A tryptophan is an essential amino acid that cannot be produced by the kidney disease (CKD) [70,71].

Tryptophan metabolism is substantially affected by the gut microbiome (Figure 3). Gut bacteria metabolize tryptophan and thus regulate its availability to the host (Table 1). Selected gut bacteria metabolize tryptophan into indole and its derivatives, such as indoleacrylic acid (IA), indole-3-acetic acid (IAA), indole-3-alddehyde (IA3), indole-3-lactic acid (ILA), and indole-3-propionic acid (IPA) [74,75]. IA is formed from indole-acetamide by bacteria that express indoleacetaldehyde dehydrogenases, including Clostridium, Bifidobacterium, and Bacteroides [76]. Tryptophan can be converted to IA3 [77] and ILA by Lactobacillus spp. and Bifidobacterium spp. [78], respectively. When Clostridium sporogenes is present, tryptophan can be converted to IPA [79]. In addition to the small intestine, a certain amount of tryptophan can reach the large intestine, where it can be decarboxylated into tryptamine by commensal bacteria expressing tryptophan decarboxylases (TrpDs) [79]. In the gut, IPA binds to pregnum X receptors (PXRs) and maintains mucosal homeostasis and barrier function [80]. IPA also increases the expression of tight junction proteins including claudin-1, occludin, and ZO-1 [81,82]. Furthermore, IPA strengthens the mucus barrier by increasing mucins (MUC2 and MUC4) and goblet cell secretion products (TF3 and RELMβ) and reduces the expression of LPS-induced inflammatory factors [82]. In addition, IPA modulates gut microbiota composition, inhibits endotoxin production and improves intestinal barrier in the gut, which is associated with protection against high-fat diet induced non-alcoholic steatohepatitis (NASH) [61].

IPA has also been shown to have direct protective effects systemically (Table 1). For example, IPA has been found to modulate mitochondrial function and improve the cardiac contractile function of isolated mouse hearts [83]. IPA increases blood pressure and cardiac contractility in normotensive rats, and increases the metabolic activity of cultured cardiomyocytes [84]. These observations are consistent with studies showing that IPA, in conjunction with the pregnane X receptor (PXR), reduces endothelium-dependent vasodilatation through suppression of eNOS-generated NO production [85]. In metabolic disorders, elevated plasma IPA concentrations were correlated with a lower risk of T2D [86,87], and reduced proportions of IPA producing bacteria were found in patients with T2D. While the mechanistic details for these associations have yet to be determined, clinical studies have shown that the protective effect of IPA could be related to insulin sensitivity and pancreatic beta-cell function [88].

6.2. Phenylalanine

Like tryptophan, phenylalanine is another essential amino acid obtained solely through dietary sources [89]. The association of phenylalanine with human disease is well-documented through the discovery of phenylketonuria (PKU) nearly 100 years ago due to deficiency of phenylalanine hydroxylase [90]. The resulting elevation of circulating phenylalanine levels leads to neurotoxicity and intellectual disability, although it can generally be prevented by restricting protein intake from an early age. The majority of phenylalanine is absorbed in the small intestine whereas the small fraction that reaches the large intestine can be metabolized by gut bacteria to phenylpyruvic acid. Interestingly, phenylpyruvic acid was the compound first identified as being present in high concentrations in the urine of PKU patients [91] since it can also be generated from excess phenylalanine in the liver by endogenous L-amino acid oxidases.

Nemet and colleagues [92] recently compared the plasma metabolomics profiles of ~1200 subjects from the GeneBank study with and without T2D to identify an unknown analyte that was associated with major adverse cardiac events (MACE = myocardial infarction (MI), stroke, or death). Targeted and quantitative MS methods unambiguously identified the metabolite as phenylacetylglycine (PAG) and its adverse association with MACE was further validated in an independent, nonoverlapping set of ~4000 GeneBank subjects. For example, both diabetics and nondiabetics in the highest quartile for PAG levels had ~2-fold higher risk of incident MACE than subjects in the first quartile [92]. Circulating PAG levels (or phenylacetylglycine in mice) were markedly suppressed after administration of poorly absorbed oral antibiotics, demonstrating the obligate contribution of gut bacteria to production of PAG via the intermediate metabolite phenylacetic acid (PAA). Thus, these observations revealed a metaorganismal pathway where dietary phenylalanine is metabolized in the gut to an intermediate common to both mice and humans (PAA) that is absorbed and subsequently conjugated preferentially with either glutamine (humans) or glycine (mice) in the liver (Table 1). Follow-up functional studies demonstrated PAG enhanced platelet responsiveness in vitro and promoted thrombus formation in a mouse model of carotid artery injury [92] (Table 1). Notably, colonization of
gnotobiotic mice with a genetically engineered strain of *C. sporogenes* lacking one of the enzymes (*flodH*) that would shunt phenylalanine metabolism towards PAA increased thrombotic potential and decreased the time to cessation of blood flow in the carotid artery injury model. Further mechanistic studies demonstrated that the platelet activating properties of PAG are mediated through G-protein coupled receptors. Based on the structural similarity of PAG to catecholamines, such as isoproterenol and epinephrine, the authors hypothesized that PAG exerts its biological effects through adrenergic receptors (ADRs). Consistent with this notion, genetic and pharmacological perturbation experiments provided evidence that PAG promotes platelet aggregation in *vivo* and thrombus formation in mice via activation of ADR isoforms present on platelets (α2A, α2B, and β2). Interestingly, PAG levels were higher in urine samples from centenarians relative to those from non-centenarians, suggesting that increased excretion of PAG was associated with longevity. This may imply that PAG has pleiotropic effects that differentially modulate multiple metabolic processes and pathophysiologies [93]. Taken together, these studies provided another elegant demonstration of the power of untargeted metabolomics combined with common natural variation to identify novel pathways associated with cardiometabolic risk through interactions between dietary phenylalanine, gut bacteria, and host metabolism.

6.3. Histidine

As one of the least abundant amino acids [94], histidine is a nutritionally essential amino acid with unique chemical and metabolic properties such as containing a imidazole ring that functions in pH buffering, metal ion chelation, and antioxidation [95–98]. There are common and unique pathways of histidine metabolism. Histidine can be converted to glutamate, and then oxidized to α-ketoglutarate by glutamate dehydrogenase [99]. In addition to protein turnover and glutamate generation, some unique metabolic pathways, including carnosine and histamine synthesis, make histidine an essential nutrient and beneficial for a number of disorders. Histidine can be microbially converted to imidazole propionate (Table 1), a metabolite that is present at higher concentrations in patients with T2D and impairs glucose tolerance and insulin signaling at the level of insulin receptor substrate [100,101]. Mechanistically, imidazole propionate activates p38γ MAPK, which promotes p62 phosphorylation and subsequently activates mTORC1 [100]. In the heart, imidazole propionate protects against radiation-induced lung and heart toxicity, thus attenuating systolic dysfunction [102]. Human *Lactobacillus reuteri* strains contain the *hdc* gene cluster, including the histidine decarboxylase (HDC) and histidine-histamine antipporter genes, and convert histidine to histamine in the gut. Histamine is an important regulator of gastrointestinal functions, such as immune responses, gastric acid production, and mucosal ion secretion. Histamine activates histamine H2 receptor and suppresses intestinal inflammation in a mouse colitis model [103]. There are four G protein-coupled histamine receptors in humans and the predominant receptors in the intestinal epithelium are H1R and H2R [104,105].

6.4. Tyrosine

Tyrosine is another non-essential amino acid that serves as the precursor to various products, including neurotransmitters, hormones, alkaloids, phenols, and pigments. Phenols, such as p-cresol, are microbial metabolites of tyrosine [106,107] and have reported to increase paracellular permeability and reduces epithelial barrier function in a concentration-dependent manner [108,109]. Similarly, p-cresol exhibits cytotoxicity and reduces endothelial barrier function [109,110]. P-cresol sulfate, a sulfate-conjugate of p-cresol, has also been found to suppress contact hypersensitivity response (Th1-type cellular immune responses) and protect against allergic airway inflammation in mice [111,112]. In addition, increased p-cresol sulfate levels have been associated with CKD [113,114] (Table 1).

6.5. Branched-chain amino acids (BCAAs)

The BCAAs (leucine, valine and isoleucine) are also essential amino acids abundant in the diet. Among other emerging microbiota-derived compounds, BCAAs serve as important nutrients in bacterial physiology and have multiple functions. Elevated circulating BCAA levels have been found to be associated with obesity, insulin resistance, T2D [115,116] and risk of certain cancer [117,118]. Similarly, Ottosson et al. found that BCAAs were positively associated with BMI (body mass index), HOMA-IR (homeostatic model assessment for insulin resistance), and the abundance of *Blautia* [119]. The depletion of species
belonging to the Bacteroides genus in obese individuals has been associated with higher levels of circulating BCAAs [120]. Additionally, cecal BCAA levels were higher in mice transplanted with gut bacteria from an obese human, suggesting that microbiota of obese individuals may have a higher capacity for producing BCAAs [121]. Furthermore, obese mice supplemented with Bacteroides dorei and Bacteroides vulgatus exhibited improved BCAA catabolism in brown adipose tissue and attenuated weight gain [122]. Together, these studies suggest that variation in intestinal microbiota may represent a potential mechanistic link between BCAA metabolism, and metabolic disease (Table 1).

7. METABOLITES DERIVED FROM STEROLS

7.1 Primary and Secondary Bile Acids

Dietary lipids represent another class of nutrients that can affect systemic host health, gut microbial composition, and derived circulating metabolites [31,123]. For example, germ-free mice exhibit altered cholesterol metabolism, and studies have shown that gut microbiota influences cholesterol metabolism [6], in part through regulating cholesterol biosynthesis in the liver [124]. Human and animal studies also indicate that probiotics can decrease systemic blood lipids by redistributing cholesterol from plasma to the liver and/or by affecting gut cholesterol absorption [125], although how probiotics decrease cholesterol levels remains poorly understood. Recently, Kenny et al. reported that coproprostol-forming bacteria can potentially decrease cholesterol absorption in the intestine resulting in lower serum levels [126]. Another aspect of the relationship between the microbiome and sterols are bile acids (BAs) (Table 1). For example, primary BAs in the form of cholic acid, chenodeoxycholic acid, and, to a lesser extent, hyocholic acid are synthesized in the liver from cholesterol and conjugated to glycine or taurine [127]. Conjugated BAs are stored in the gallbladder and secreted into the small intestine upon ingestion of a meal, where they help emulsify and solubilize fats and facilitate the transport of nutrients. While most are reabsorbed in the distal small intestine and returned to the gallbladder, a small amount (~5%) of BAs enters the colon where they are subjected to structural modifications by gut micro-organisms through deconjugation-, dehydrogenation, and dihydroxylation to generate deoxycholic acid, lithocholic acid, hyodeoxycholic acid, and many other so-called secondary BAs [127]. Deconjugation of host-derived primary BAs occurs via bile salt hydrolases (BSH), which are widespread in bacteria. Bile salts may provide nutrition for bacteria by liberating amino acids and could aid in the incorporation of cholesterol and bile components in the bacterial membranes. The hydroxylation reactions are carried out by three distinct hydroxy steroid hydrox-ogenases, 3α-, 7α-, and 12α-, which result in the oxidation of specific hydroxyl groups on BAs. There has been speculation that the diversity metabolites resulting from these reactions may act as signaling molecules for microbes to communicate with each other or alter host physiology. 7α-dehydroxylation, is only known to be performed by a small number of anaerobic species. Since BAs can be toxic to bacteria, not only can gut microbiota influence BA pools, but BA pools can conversely affect the structure of gut microbial communities. Other potential mechanisms through which BAs are thought to influence cardiometabolic pathways may be related to their direct activation of cellular receptors, such as the nuclear receptor farnesoixoid X receptor (FXR) and the membrane Takeda G-protein coupled receptor 5 (TGR5) [128]. Most of our understanding on how BAs influence cardiometabolic traits comes from in vitro studies, the use of genetically modified animal models, or indirectly through the use of FXR and TGR5 agonists/antagonists. For example, FXR and TGR5 have been shown to regulate glucose, lipid, and energy metabolism [129–133], vascular wall inflammation [134–136], atherosclerosis [137,138], and cardiac function [139,140]. Although technical difficulties and biological differences between mice and humans have hampered progress in this area to some extent, limited clinical associations between circulating BAs and cardiometabolic outcomes in human cohorts have been reported. For example, a small clinical trial with the secondary BA, ursodeoxycholic acid (UDCA), demonstrated improvements in liver function scores [141]. In a more recent study, levels of glycoursoxydeoxycholic (GUDCA, the glycine-conjugated form of UDCA) were lower in serum and stool of hyperglycemic subjects, and ameliorated diet-induced insulin resistance and hepatic steatosis when fed to mice [142]. However, BA composition differs significantly between humans and mice, including their conjugation to glycine (humans) or taurine (mice). These observations suggest that mice studies investigating the interactions between gut microbiota, host BA metabolism, and cardiometabolic traits may need to be interpreted with caution if being used to gain insight into human diseases [143]. The varying affinities that different BAs have towards FXR and TGR5 further complicate efforts to a better understanding of the role of these metabolites in cardiometabolic disease [144–147]. Lastly, studies evaluating total BA levels by enzyme immunoassays for association with CAD have been inconsistent [148,149]. Some of these challenges may be overcome with technological advances, such as the recent development of quantitative MS assays to simultaneously measure a large panel of primary and secondary BAs in human plasma [150].

8. MICROBIOME-ACCESSIBLE CARBOHYDRATES (MACS)

8.1. Short-chain Fatty Acids (SCFAs)

SCFAs are among the most abundant and most highly studied gut microbial metabolites. They are produced by anaerobic fermentation of carbohydrates reaching the distal gut, including dietary fiber and prebiotics [12,151]. The main SCFAs in the gut are acetate, propionate, and butyrate (Table 1), which are produced at a ratio of ~60:20:20, respectively, and a combined luminal concentration of ~100 mM [12,152]. However, establishing accurate concentrations of SCFAs in the gut or feces is difficult considering the dynamic nature between substrate availability, bacterial production, and colonic absorption. Nonetheless, some of the beneficial properties of dietary fiber can be attributed to its modulation of the gut microbiome and production of these beneficial SCFAs. For example, studies have shown that SCFAs can modulate epithelial turnover and strengthen tight junctions [153]. In particular, butyrate influences epithelial oxygen consumption and stabilizes hypoxia-inducible factor, which is critical for maintenance of epithelial barrier function [154]. Once produced in the intestinal lumen, SCFAs are transported into colonocytes, where they serve as substrates for energy and metabolism. Butyrate induces intestinal glucose production by regulating gluconeogenic gene expression whereas propionate serves as a substrate for intestinal gluconeogenesis [155]. The remaining SCFAs are shuttled to the liver via the portal vein where acetate, for example, is integrated into the circulating acetate pool, which consists of both bacterially-derived and host-produced acetate [156]. SCFAs are mainly excreted through feces, lungs and, to a less extent, via urine [151,157,158]. Although SCFAs concentrations are present in peripheral blood at significantly lower levels compared to the gut and portal circulation, circulating butyrate levels are inversely related to endotoxemia and systemic inflammation [159].
SCFAs have been shown to modulate several cardiometabolic health traits including lipid metabolism, glucose homeostasis, inflammation, and atherosclerosis. In diabetics, butyrate supplementation led to a reduction in serum cholesterol and triglycerides and improved glucose tolerance [166]. A clinical trial with T2D patients demonstrated that dietary supplementation of butyrate and insulin, a type of dietary fiber, resulted in improved glycemic homeostasis [161]. Furthermore, bidirectional Mendelian randomization (MR) analysis revealed that host genetic-driven increase in gut production of butyrate was associated with improved insulin responses in a large human cohort of normoglycemic individuals [162]. These observations are consistent with the lower levels of butyrate-producing bacteria displayed by cardiometabolic disease patients compared to healthy individuals [163]. Several studies have demonstrated that SCFAs can also have anti-inflammatory effects [164]. Indeed, immunomodulation is associated with many of the cardiometabolic benefits of SCFAs. For example, Aoki et al. demonstrated that bacterially-produced acetate ameliorated non-alcoholic fatty liver disease and suppressed hepatic inflammation in mice [165]. In addition, studies by Kasahara and colleagues [166] revealed that the prominent gut-associated butyrate producing bacterial genus Roseburia was negatively correlated with atherosclerosis. Gnotobiotic studies subsequently implicated butyrate in protection against aortic lesion development [166]. More recently, an atheroprotective effect of propionate has also been reported [167]. For example, in mice, propionate was shown to attenuate aortic lesion formation and lower plasma total cholesterol and LDL cholesterol levels, which could be attributed, in part, to decreased expression of intestinal cholesterol absorption genes [167]. Notably, a small 8-week clinical intervention with propionate in healthy volunteers also led to a more favorable lipid profile.

Although circulating concentrations of SCFAs, especially propionate and butyrate, are significantly lower relative to their intestinal levels, SCFAs demonstrate systemic effects on host metabolism [164]. There are four known G protein-coupled receptors that sense SCFAs (GPR41, GPR43, GPR109a, Olf78), each of which exhibit differing affinities for each SCFA and present unique tissue expression patterns [168]. Although they are all expressed in the intestine, these receptors are also expressed in peripheral tissues, including the pancreas, adipose, spleen, and various immune cells [168]. Circulating concentrations of SCFAs tend to be lower than the reported half-maximal effective concentrations of these receptors suggesting that low-level activation may be sufficient to trigger physiological effects. SCFAs are also known to reduce systemic inflammation by promoting mucosal health and improve gut barrier function [164], thus limiting translocation of proinflammatory material such as lipopolysaccharide (LPS) from the intestine into systemic circulation.

**9. SUMMARY AND FUTURE PROSPECTS**

Population-based integrative approaches have identified a large number of microbe-derived or microbe-modified metabolites that are associated with cardiometabolic traits, and many of these have been verified by experimental approaches such as the use of germ-free mice. It is important to note that, because population-based genetics approaches only generate hypotheses, direct experiments are essential to validate the causal relationships. The metabolites in some cases act directly on intestinal cells but, in most cases, enter the host circulation and interact with specific target cells and tissues. In many cases, the mechanisms by which the metabolites exert their effects are still unclear. An important problem in human studies is the inability to obtain tissue samples other than blood. Studies in mouse populations offer the advantage that omics data can be collected from relevant tissues and that the environments can be controlled [35]. Two important additional applications of such integrative approaches are to determine how the gut microbiome composition is influenced by host genetic variation and by diet/lifestyle. However, the mapping power of 100 inbred strains in the HMDP is limited as compared with human GWASs with thousands of samples. Meta-analysis incorporating data from traditional crosses or more inbred and recombinant inbred strains can be used to improve power [169–171]. Of note, it is essential to correct population mapping to avoid false positive associations. This can be accomplished by mixed model algorithms including EMMA and FaST-LMM [172,173]. Simulation, a Bonferroni correction, or a false discovery rate can be used to determine genome-wide significance [174,175].

An important aspect of systems-based approaches is the ability to integrate multiple levels of data. Studies with mouse populations provide an advantage since omics data can be collected directly from tissues relevant to cardiometabolic outcomes, such as the vasculature, liver, adipose, and intestines. Such data combined with genetic variation, gut bacterial composition, and clinical phenotypes allows correlation, co-mapping, or various modeling analyses to be carried out, which can generate more directed hypotheses regarding the relationships between the various levels of data. This approach was illustrated by Org and colleagues in an HMDP study where coincident genome-wide significant association of Roseburia spp. abundance and subcutaneous fat mass were observed with a locus on chromosome 15. Because of the availability of transcriptomics data in adipose and liver tissues, the authors were further able to show that the same locus yielded expression quantitative trait loci (eQTL) for several positional candidate genes. Furthermore, of the positional candidates at this locus, mRNA levels of Itak4, which is involved in the innate immune response, were correlated with both the abundance of Roseburia spp. and insulin resistance, suggesting a causal relationship with this gene [34]. Similar approaches have also been applied to other mouse populations, including advanced intercross lines, the collaborative cross, and diversity outbred mice [35]. By comparison, the gold standard for establishing causality in humans is the randomized clinical trial, which can be challenging and expensive to carry out. More recently, Mendelian randomization (MR) with genetic data is another strategy that has proven useful for establishing causal relationships. For example, several MR studies have suggested that various bacterial taxa or gut microbiome-derived metabolites are causally associated with cardiometabolic traits [162,176]. However, validation in additional studies with larger sample sizes will be needed before such causal relationships are firmly established. Some cohorts, such as the Metabolic Syndrome in Men (METSIM) study, a population-based study of ~10,000 Finnish men, are promising in this regard since multi-omic data are available [177]. Despite its strengths, systems studies with omics data are still comprehensive screens for associations between various levels of data (i.e., gut bacteria, metabolites, clinical traits) that are not necessarily quantitative. Thus, it is critical to verify any identified associations with independent methods and validation cohorts to avoid potential false positive signals. In this regard, using an appropriate statistical threshold that considers the large number of comparisons made in systems studies is one important component to using rigorous experimental designs.

It is important to note that in addition to the vast metabolic diversity observed in the gut microbiome, it is also becoming evident that there is a high degree of functional redundancy [178]. For example, it is uncommon that a single bacterial strain or even a species to be responsible for production of a metabolite [56,63]. Thus, microbiome analyses should consider candidate microbial pathways, ideally...
expression levels (mRNA or protein) of the genes contributing to production of bioactive metabolites, rather than just quantitation of the abundance of taxa previously described to have such capabilities. Furthermore, functional predictions based on sequence homology should be considered as hypotheses and require direct experimental confirmation, as it is becoming clear that the presence of a gene encoding a specific enzyme does not necessarily result in such enzymatic activity being expressed [63].

Given the associations between gut microbiota and cardiometabolic outcomes, developing new therapeutic strategies targeting the gut microbial communities is a promising approach to prevent or treat these diseases. Considerable effort into developing strategies has been used to achieve this goal [179], including prebiotics [180,181], probiotics [182–184], fecal microbiota transplantation [185,186], metabolites [187–191], phages [192,193], miRNAs [194], and hyaluronan [195,196]. In particular, studies in mice have demonstrated that transplantation of cecal microbes from an atherosclerosis-prone strain with high TMA/TMAO levels to a low TMAO-producing and atherosclerosis-resistant strain can enhance production of these pro-atherogenic metabolites with a corresponding increase in aortic lesion formation [197]. These observations raise the intriguing question of whether using the converse strategy with bacterial transplantation from individuals with low TMA/TMAO-producing capacity, such as vegans [53], can decrease risk of CAD. Although such approaches have yet to be implemented in humans with respect to CAD, fecal transplantation studies have shown that transfer of gut microbes from lean donors through a duodenal infusion into patients with metabolic syndrome can improve insulin sensitivity [198]. In another strategy, a small molecule choline analog, 3, 3-dimethyl-1-butanol (DMB), was designed to competitively inhibit diverse and phylogenetically distant classes of microbial TMA lyases, which were previously identified as enzymes that catalyze the conversion of choline to TMA [51,199]. Chronic feeding of DMB to mice in the context of a high-choline diet led to shifts in the proportions of some bacterial taxa and substantial reductions in plasma TMAO levels, macrophage cholesterol accumulation, foam cell formation, and atherosclerotic lesions, without any evidence of toxicity or adverse cardiometabolic effects in the animals [200].

Lastly, another promising approach may be to remodel gut bacterial composition through the use of cyclic D, l-α-epitides. For example, chronic oral administration of several different cyclic peptides to hyperlipidemic atherosclerosis-prone mice shifted the gut microbiota from a high-fat state to one resembling a chow diet and reduced cholesterol levels and aortic lesion formation [201]. Taken together, these results suggest that targeting gut microbial composition or production of bacterial-derived metabolites through transplantation or specific pharmacological manipulation may serve as potentially novel therapeutic approaches for treating cardiometabolic disease.

ACKNOWLEDGMENTS

This study was supported by funds from NIH HL144651 (A.J.L., F.E.R.), NIH HL148577 (F.E.R., A.J.L.), NIH HL147883, NIH DK117850 (A.J.L.), NIH HL148110 (A.J.L., H.A.), NIH HL133169 (H.A.), and MANTP T32 DK 007665 (E.H.).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

[1] Li, H., Wang, X., Rukina, D., Huang, Q., Lin, T., Sorrentino, V., et al., 2018. An integrated systems genetics and omics toolkit to probe gene function. Cell Systems 6:90–102 e4.
[2] Seldin, M., Yang, X., Luis, A.J., 2019. Systems genetics applications in metabolism research. Nature Medicine 1:1038–1050.
[3] Backhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., et al., 2004. The gut microbiota as an environmental factor that regulates fat storage. Proceedings of the National Academy of Sciences of the United States of America 101:15718–15723.
[4] Backhed, F., Manchester, J.K., Semenikovitch, C.F., Gordon, J.I., 2007. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences of the United States of America 104:979–984.
[5] Kreznar, J.H., Keller, M.P., Traeger, L.L., Rabaglia, M.E., Schueller, K.L., Stapleton, D.S., et al., 2017. Host genotype and gut microbiome modulate insulin secretion and diet-induced metabolic phenotypes. Cell Reports 18:1739–1750.
[6] Rabot, S., Membrez, M., Bruneau, A., Girard, P., Harach, T., Moser, M., et al., 2010. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. The FASEB Journal 24:4948–4959.
[7] Lee, W.J., Hase, K., 2014. Gut microbiota-generated metabolites in animal health and disease. Nature Chemical Biology 10:416–424.
[8] Schroeder, B.O., Bäckhed, F., 2016. Signals from the gut microbiota to distant organs in physiology and disease. Nature Medicine 22:1079–1089.
[9] Molinero, N., Ruiz, L., Sanchez, B., Margolles, A., Delgado, S., 2019. Intestinal bacterial interplay with bile and cholesterol metabolism: implications on host physiology. Frontiers in Physiology 10:185.
[10] Dodd, D., Spitzer, M.H., Van Treuren, W., Merrill, B.D., Hryckowian, A.J., Higginsbottom, S.K., et al., 2017. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 551:648–652.
[11] Husted, A.S., Traulsen, M., Rudenko, O., Hjorth, S.A., Schwartz, T.W., 2017. GPCR-mediated signaling of metabolites. Cell Metabolism 25:777–796.
[12] Klauckramer, K.A., Fan, J., Bäckhed, F., 2021. Gut microbiome as multi-kingdom intermediates. Nature Reviews Microbiology 19:77–94.
[13] den Besten, G., van Eunen, K., Groen, A.K., Venema, K., Reijngoud, D.J., Bakker, B.M., 2013. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of Lipid Research 54:2325–2340.
[14] van der Hee, B., Wells, J.M., 2021. Microbial regulation of host physiology by short-chain fatty acids. Trends in Microbiology 29:700–712.
[15] Rastelli, M., Cani, P.D., Krauf, C., 2019. The gut microbiome influences host endocrine functions. Endocrine Reviews 40:1271–1284.
[16] Rinninella, E., Raoul, P., Cintori, M., Franceschi, F., Miggiano, G.A.D., Gasbarrini, A., et al., 2019. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7:14.
[17] Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., et al., 2011. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57–63.
[18] Ashida, H., Ogawa, M., Kim, M., Mimuro, H., Sasakawa, C., 2011. Bacteria and host interactions in the gut epithelial barrier. Nature Chemical Biology 8:36–45.
[19] Vaishnava, S., Yamamoto, M., Severson, K.M., Ruhn, K.A., Yu, X., Koren, O., et al., 2011. The antibacterial lectin Reglligamma promotes the spatial segregation of microbiota and host in the intestine. Science 334:255–258.
Review

[20] Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., et al., 2007. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761–1772.

[21] Kitai, T., Nemet, I., Engelman, T., Morales, R., Chaikijurajai, T., Morales, K., et al., 2022. Intestinal barrier dysfunction is associated with elevated right atrial pressure in patients with advanced decompensated heart failure. American Heart Journal 245:78–80.

[22] Rutyayisire, E., Huang, K., Liu, Y., Tao, F., 2016. The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants’ life: a systematic review. BMC Gastroenterology 16:86.

[23] Schwartz, D.J., Langdon, A.E., Dantas, G., 2020. Understanding the impact of antibiotic perturbation on the human microbiome. Genome Medicine 12:62.

[24] Allais, L., Kerckhof, F.M., Verschuere, S., Bracke, K.R., De Smet, R., Laukens, D., et al., 2016. Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environmental Microbiology 18:1352–1363.

[25] O’Toole, P.W., Jeffery, I.B., 2015. Gut microbiota and aging. Science 350:1214–1215.

[26] Wilfamski, T., Diener, C., Rappaport, N., Patwardhan, S., Wilmanski, T., Diener, C., Rappaport, N., Patwardhan, S., Wiedrick, J., Lapidus, J., et al., 2021. Gut microbiome pattern reflects healthy aging and predicts survival in humans. Nature Metabolism 3:274–286.

[27] Ghosh, T.S., Rampelli, S., Jeffery, I.B., Santoro, A., Neto, M., Capri, M., et al., 2020. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut 69:1218–1228.

[28] Sonnenburg, E.D., Sonnenburg, J.L., 2014. Starving our microbial self: the interactions. Genome Research 25:1558–1569.

[29] Caesar, R., Tremaroli, V., Kovatcheva-Datchary, P., Cani, P.D., Backhed, F., Org, E., Parks, B.W., Joo, J.W., Emert, B., Schwartzman, W., Kang, E.Y., Blaschke, T.A., et al., 2015. Genetic and environmental control of host-gut microbiota in- teractions. Drug Discovery Today: Disease Models 28:61–78.

[30] Wilmanski, T., Diener, C., Rappaport, N., Patwardhan, S., Wiedrick, J., Lapidus, J., et al., 2021. Gut microbiome pattern reflects healthy aging and predicts survival in humans. Nature Metabolism 3:274–286.

[31] Falony, G., et al., 2020. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. Nature Microbiology 5:1079–1087.

[32] Liu, X., Tang, S., Zhong, H., Tong, X., Jie, Z., Ding, Q., et al., 2021. A genome-wide association study for gut metagenome in Chinese adults illuminates complex diseases. Cell Discovery 7:9.

[33] Sonnenburg, E.D., Sonnenburg, J.L., 2014. Starving our microbial self: the interactions. Genome Research 25:1558–1569.

[34] Zeevi, D., et al., 2018. Environment dominates over host genetics in shaping human gut microbiota. Nature 555:210–215.

[35] Buffa, J.A., Romano, K.A., Copeland, M.F., Cody, D.B., Zhu, W., Galvez, R., et al., 2022. The microbial gbu gene cluster links cardiovascular disease risk associated with red meat consumption to microbiota L-carnitine catalabolism. Nature Microbiology 7:73–86.

[36] Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., et al., 2013. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine 19:576–581.
Review

[91] Folling, A., 1934. The excretion of phenylpyruvic acid in the urine, an anomaly of metabolism in connection with imbecility. Zeitschrift fur Physiologische Chemie 227:169–176.

[92] Nemel, I., Saha, P.P., Gupta, N., Zhu, W., Romano, K.A., Skye, S.M., et al., 2020. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors. Cell 180:862–877 e22.

[93] Collino, S., Montoliu, I., Martin, F.P., Scherer, M., Mari, D., Salvioli, S., et al., 2013. Metabolic signatures of extreme longevity in northern Italian centenarians reveal a complex remodeling of amino acids, and gut microbiota metabolism. PLoS One 8.e56564.

[94] Tessari, P., 2019. Nonessential amino acid usage for protein replenishment in humans: a method of estimation. American Journal of Clinical Nutrition 110:255–264.

[95] Derave, W., Everaert, I., Beeckman, S., Baguet, A., 2010. Muscle carnosine metabolism and beta-alanine supplementation in relation to exercise and training. Sports Medicine 40:247–263.

[96] Poon, I.K., Patel, K.K., Davis, D.S., Parish, C.R., Hulett, M.D., 2011. Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood 117:2093–2101.

[97] Dahl, T.A., Midden, W.R., Hartman, P.E., 1988. Some prevalent biomolecules as defenses against singlet oxygen damage. Photochemistry and Photobiology 47:357–362.

[98] Hartman, P.E., Hartman, Z., Ault, K.T., 1990. Scavenging of singlet molecular oxygen by imidazole compounds: high and sustained activities of carboxy terminal histidine dipeptides and exceptional activity of imidazole-4- acetic acid. Photochemistry and Photobiology 51:59–66.

[99] Brosnan, M.E., Brosnan, J.T., 2020. Histidine metabolism and function. Journal of Nutrition 150:2570S–2575S.

[100] Koh, A., Molinano, A., Stahlan, M., Khan, M.T., Schmidt, C., Manner-Holm, L., et al., 2018. Microbiologically produced imidazole propionate impairs insulin signaling in mTORC1. Cell 175:947–961 e17.

[101] Molinano, A., Bel Lassen, P., Henricsson, M., Wu, H., Adriouch, S., Belda, E., et al., 2020. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nature Communications 11:5881.

[102] Chen, Z., Wang, B., Dong, J., Li, Y., Zhang, S., Zeng, X., et al., 2021. Gut microbiota-derived l-histidine/imidazole propionate axis fights against the radiation-induced cardiopulmonary injury. International Journal of Molecular Sciences 22.

[103] Gao, C., Major, A., Rendon, D., Lugo, M., Jackson, V., Shi, Z., et al., 2015. Histamine H2 receptor-mediated suppression of intestinal inflammation by probiotic lactobacillus reuteri. miBio 6:e00158, 15.

[104] O’Mahony, L., Akdis, M., Akdis, C.A., 2011. Regulation of the immune response and inflammation by histamine and histamine receptors. The Journal of Allergy and Clinical Immunology 128:1153–1162.

[105] Sander, L.E., Lorentz, A., Sellge, G., Coeffler, M., Neipp, M., Veres, T., et al., 2006. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut 55:498–504.

[106] Safai, Y., Sato, T., Nomoto, K., Tsuji, H., 2018. Identification of phenol- and p-cresol-producing intestinal bacteria by using media supplemented with tyrosine and its metabolites. FEMS Microbiology Ecology 94.

[107] Windy, K., De Preter, V., Verbeke, K., 2012. Relevance of protein fermentation to gut health. Molecular Nutrition & Food Research 56:184–196.

[108] Hughes, R., Kurth, M.J., McGilligan, V., McGlynn, H., Rowland, I., 2008. Effect of colonic bacterial metabolites on Caco-2 cell paracellular permeability in vitro. Nutrition and Cancer 60:259–266.

[109] Verbeke, K.A., Boobis, A.R., Chiiodini, A., Edwards, C.A., Franck, A., Kleerebezem, M., et al., 2015. Towards microbial fermentation metabolites as markers for health benefits of probiotics. Nutrition Research Reviews 28:42–66.

[110] Andriamihaja, M., Lan, A., Beaumont, M., Audebert, M., Wong, X., Yamada, K., et al., 2015. The deleterious metabolic and genotoxic effects of the bacterial metabolite p-cresol on colon epithelial cells. Free Radical Biology and Medicine 85:219–227.

[111] Shiba, T., Kawakami, K., Sasaki, T., Makino, I., Kato, I., Kobayashi, T., et al., 2014. Effects of intestinal bacteria-derived p-cresyl sulfate on Th1-type immune response in vivo and in vitro. Toxicology and Applied Pharmacology 274:191–199.

[112] Wypych, T.P., Pattaroni, C., Perdijk, O., Yap, C., Trompetta, A., Anderson, D., et al., 2021. Microbial metabolism of L-tyrosine protects against allergic airway inflammation. Nature Immunology 22:279–286.

[113] Ito, S., Yoshida, M., 2014. Protein-bound urmic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins 6:665–678.

[114] Meyer, T.W., Hostetter, T.H., 2012. Uremic solutes from colon microbes. Kidney International 81:949–954.

[115] Gjøda, J., Cahova, M., 2021. Gut microbiota as the link between elevated BCAA serum levels and insulin resistance. Biomolecules 11.

[116] Newgard, C.B., An, J., Bain, J.R., Muehlbauer, M.J., Stevens, R.D., Lien, L.F., et al., 2009. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism 9:311–326.

[117] Katagiri, R., Goto, A., Nakagawa, T., Nishiumi, S., Kobayashi, T., Hidaka, A., et al., 2018. Increased levels of branched-chain amino acid associated with increased risk of pancreatic cancer in a prospective case-control study of a large cohort. Gastroenterology 155:1474–1482 e1.

[118] Tobias, D.K., Hazra, A., Lawler, P.R., Chandler, P.D., Chasman, D.I., Buring, J.E., et al., 2020. Circulating branched-chain amino acids and long-term risk of obesity-related cancers in women. Scientific Reports 10:16534.

[119] Ottosson, F., Brunkwall, L., Ericson, U., Nilsson, P.M., Almgren, P., Fernandez, C., et al., 2018. Connection between BMI-related plasma metabolite profile and gut microbiota. The Journal of Clinical Endocrinology and Metabolism 103:1491–1501.

[120] Liu, R., Hong, J., Xu, X., Feng, Q., Zhang, D., Gu, Y., et al., 2017. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nature Medicine 23:859–868.

[121] Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L., et al., 2013. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341:1241214.

[122] Yoshida, N., Yamashita, T., Osone, T., Hosooka, T., Shinozuka, M., Kitahama, S., et al., 2021. Bacteroides spp. promotes branched-chain amino acid catabolism in brown fat and inhibits obesity. iScience 24:103342.

[123] Schoeller, M., Caesar, R., 2019. Dietary lipids, gut microbiota and lipid metabolism. Reviews in Endocrine & Metabolic Disorders 20:461–472.

[124] Le Roy, T., Lécuyer, E., Chaussong, B., Rhimi, M., Lhomme, M., Boudoubozez, S., et al., 2019. The intestinal microbiota regulates host cholesterol homeostasis. BMC Biology 17:94.

[125] Pereira, D.I., Gibson, G.R., 2002. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Critical Reviews in Biochemistry and Molecular Biology 37:259–281.

[126] Kennedy, D.J., Plichta, D.R., Shungin, D., Koppel, N., Hall, A.B., Fu, B., et al., 2020. Cholesterol metabolism by uncultured human gut bacteria influences host cholesterol level. Cell Host & Microbe 28:245–257 e6.

[127] Ridlon, J.M., 2020. Conceptualizing the vertebrate sterolbiome. Applied and Environmental Microbiology 86.

[128] Vitek, L., 2017. Bile acids in the treatment of cardiometabolic diseases. Annals of Hepatology 16(Suppl 1):S52.

[129] Carlu, B., van Harmelen, K., Duran-Sandoval, D., van Dijk, T.H., Greffhorst, A., Abdelkarim, M., et al., 2006. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. Journal of Biological Chemistry 281:11039–11049.
Pathak, P., Xie, C., Nichols, R.G., Ferrell, J.M., Boehme, S., Krausz, K.W., et al., 2018. Fasting farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 68:1574–1588.

Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., et al., 2009. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 10:167–177.

Watanabe, M., Houten, S.M., Matakia, C., Christoffolete, M.A., Kim, B.W., Pathak, P., Xie, C., Nichols, R.G., Ferrell, J.M., Boehme, S., Krausz, K.W., Watanabe, M., Houten, S.M., Mataki, C., Christoffolete, M.A., Kim, B.W., Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., et al., 2018. Increased serum bile acids level is associated with high-risk coronary artery plaques in an asymptomatic population detected by coronary computed tomography angiography. Journal of Thoracic Disease 11:5063–5070.

Choucair, I., Nemet, I., Li, L., Cole, M.A., Skye, S.M., Kirshp, J.D., et al., 2020. Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases. Journal of Lipid Research 61:159–177.

Boets, E., Gomand, S.V., Derovers, L., Preston, T., Vermeulen, K., De Preter, V., et al., 2017. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. Journal of Physiology 595:541–555.

Cummings, J.H., Pomare, E.W., Branch, W.J., Naylor, C.P., Macfarlane, G.T., 1987. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221–1227.

Yu, L.C., Wang, J.T., Wei, S.C., Ni, Y.H., 2012. Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. World Journal of Gastrointestinal Pathophysiology 3:27–43.

Kelly, C.J., Zheng, L., Campbell, E.L., Saeedi, B., Scholz, C.C., Bayless, A.J., et al., 2015. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host & Microbe 17:662–671.

De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Viner, J., Zitoun, C., Duchamp, A., et al., 2014. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156:84–96.

Knowles, S.E., Jarrett, I.G., Fisell, O.H., Ballard, F.J., 1974. Production and utilization of acetate in mammals. Biochemical Journal 142:401–411.

Chambers, E.S., Preston, T., Frost, G., Morrison, D.J., 2018. Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Current Nutrition Reports 7:198–206.

McNeil, N.I., Cummings, J.H., James, W.P., 1978. Short chain fatty acid absorption by the human large intestine. Gut 19:819–822.

Juanola, O., Ferrusquia-Vaca, J., Garcia-Villalba, R., Zapat, P., Magaz, M., Marin, P., et al., 2019. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. The FASEB Journal 33:11595–11605.

Khan, S., Jena, G., 2016. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: a comparative study with metformin. Chemico-Biological Interactions 254:124–134.

Roshanravan, N., Mahdavi, R., Alizadeh, E., Jafarabadi, M.A., Heravyati, H., Chavami, A., et al., 2017. Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with Type 2 diabetes: a randomized double-blind, placebo-controlled trial. Hormone and Metabolic Research 49:866–891.

Sanna, S., van Zuydam, N.R., Mahajan, A., Kurilshikov, A., Vich Vila, A., Vosa, U., et al., 2019. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nature Genetics 51:600–605.

Karlsson, F.H., Fåk, F., Nookaew, I., Tremaroli, V., Fagerberg, B., Petranovic, D., et al., 2012. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature Communications 3:1245.

Petranovic, D., et al., 2015. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host & Microbe 17:662–671.

From molecular metabolism to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165:1332–1347.
Tao, Y.W., Gu, Y.L., Mao, X.Q., Zhang, L., Pei, Y.F., et al., 2020. Effects of probiotics on type II diabetes mellitus: a meta-analysis. Journal of Translational Medicine 18:30.

Kimura, I., Ichimura, A., Ohue-Kitano, R., Igarashi, M., 2020. Free fatty acid receptors in health and disease. Physiological Reviews 100:171–210.

Kang, E.Y., Han, B., Farlotte, N., Joo, J.W., Shih, D., Davis, R.C., et al., 2014. Meta-analysis identifies gene-by-environment interactions as demonstrated in a study of 4,965 mice. PLoS Genetics 10:e1004022.

Ohmen, J., Kang, E.Y., Li, X., Joo, J.W., Hormozdiari, F., Zheng, Q.Y., et al., 2014. Genome-wide association study for age-related hearing loss (AHL) in the mouse: a meta-analysis. J Assoc Res Otolaryngol 15:335–352.

Rau, C.D., Parks, B., Wang, Y., Eskin, E., Simecek, P., Churchill, G.A., et al., 2015. High-density genotypes of inbred mouse strains: improved power and precision of association mapping. G3 (Bethesda) 5:2021–2026.

Dallé, B., Vervliet, B., Bergonzelli, G., Verbeke, K., Van Oudenhove, L., 2020. Colon-delivered short-chain fatty acids attenuate the cortisol response to psychosocial stress in healthy men: a randomized, placebo-controlled trial. Neuropsychopharmacology 45:2257–2266.

Descamps, H.C., Herrmann, B., Wiedu, D., Thaiss, C.A., 2019. The path toward using microbial metabolites as therapeutics. EBioMedicine 44:747–754.

Le Leu, R.K., Winter, J.M., Christophersen, C.T., Young, G.P., Humphreys, K.J., Hu, Y., et al., 2015. Butyrylated starch intake can prevent red meat-induced O6-methyl-(2-deoxyguanosine adducts in human rectal tissue: a randomised clinical trial. British Journal of Nutrition 114:220–230.

Piscotta, F.J., Hoffmann, H.H., Choi, Y.J., Small, G.J., Ashbrook, A.W., Koirala, B., et al., 2021. Metabolites with SARS-CoV-2 inhibitor activity identified from human microbiome commensals. mSphere 6:e0071121.

Yang, S., Li, X., Yang, F., Zhao, R., Pan, X., Liang, J., et al., 2019. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Frontiers in Pharmacology 10:1360.

Paule, A., Frezza, D., Edeas, M., 2018. Microbiota and phage therapy: future challenges in medicine. Medical Science 6.

Rasmussen, T.S., Koefoed, A.K., Jakobsen, R.R., Deng, L., Castro-Mejia, J.L., Brunse, A., et al., 2020. Bacteriophage-mediated manipulation of the gut microbiome - promises and presents limitations. FEMS Microbiology Reviews 44:507–521.

Liu, S., Weiner, H.L., 2016. Control of the gut microbiome by fecal microRNA. Microbiol Cell 3:176–177.

Lee, Y., Sugihara, K., Gilliland 3rd, M.G., Son, J., Kamada, N., Moon, J.J., 2020. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nature Materials 19:118–126.

Petrey, A.C., de la Motte, C.A., 2019. Hyaluronan in inflammatory bowel disease: cross-linking inflammation and coagulation. Matrix Biology 78:126–323.

Gregory, J.C., Buffa, J.A., Org, E., Wang, Z., Levison, B.S., Zhu, W., et al., 2015. Transmission of atherosclerosis susceptibility with gut microbial transplantation. Journal of Biological Chemistry 290:5667–5666.

Vrieze, A., Van Nood, E., Hollem, F., Salojarvi, J., Kootte, R.S., Bartelme, J.F., et al., 2012. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–916 e7.

Sandhu, S.S., Chase Jr., T., 1986. Aerobic degradation of choline by Proteus mirabilis: enzymatic requirements and pathway. Canadian Journal of Microbiology 32:743–750.

Gregory, J.C., Buffa, J.A., Org, E., Wang, Z., Levison, B.S., Zhu, W., et al., 2015. Transmission of atherosclerotic susceptibility with gut microbial transplantation. Journal of Biological Chemistry 290:5667–5666.

Vrieze, A., Van Nood, E., Hollem, F., Salojarvi, J., Kootte, R.S., Bartelme, J.F., et al., 2012. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–916 e7.

Sandhu, S.S., Chase Jr., T., 1986. Aerobic degradation of choline by Proteus mirabilis: enzymatic requirements and pathway. Canadian Journal of Microbiology 32:743–750.

Vrieze, A., Van Nood, E., Hollem, F., Salojarvi, J., Kootte, R.S., Bartelme, J.F., et al., 2012. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–916 e7.

Sandhu, S.S., Chase Jr., T., 1986. Aerobic degradation of choline by Proteus mirabilis: enzymatic requirements and pathway. Canadian Journal of Microbiology 32:743–750.

Vrieze, A., Van Nood, E., Hollem, F., Salojarvi, J., Kootte, R.S., Bartelme, J.F., et al., 2012. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–916 e7.

Sandhu, S.S., Chase Jr., T., 1986. Aerobic degradation of choline by Proteus mirabilis: enzymatic requirements and pathway. Canadian Journal of Microbiology 32:743–750.